Study of different treatment strategies for essential thrombocythaemia patients who presented to the Launceston General Hospital, Tasmania, Australia

Not Applicable

Completed

• Conditions: Essential thrmbocythaemia; Blood - Haematological diseases; Cancer - Thrombocythaemia

• Registration Number: ACTRN12611000805976
• Lead Sponsor: Clifford Craig Medical Trust Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-08-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

patients over 18 years of age with essential thrombocythaemia who are presented to Launceston General Hospital during the period of August 2011- August 2012

Exclusion Criteria

Patients who have transient or reactive thrombocytosis or below age of 18 years.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To record any complications of the disease or side effects of the treatment for future references. These complications include bleeding, thrombosis and disease progression.[12 months];To assess platelet counts in patients with essential thrombocythaemia after treatment with different anti-platelets agents e.g. Hydroxyurea, anagerlide and interferon alpha.[12 months];To determine the risk factors for essential thrombocythaemia that may influence treatment-response. This will be assessed by molecular studies in addition to full blood counts.[12 months]

Secondary Outcome Measures

Name	Time	Method
To document the treatment modalities or any other related data such as Haemoglobin and WCC profile for these patients.[12 months];To assess the prevalence of essential thrombocythaemia among northern Tasmania patients.[12 months]